Co-Diagnostics Inc gross margin has been in long-term decline. The average rate of decline per year is -6.2%.
The historical rank and industry rank for Co-Diagnostics's Gross Margin % or its related term are showing as below:
HAM:C970'
s Gross Margin % Range Over the Past 10 Years
Min: 38.56 Med: 77.5 Max: 88.18
Current: 45.13
During the past 11 years, the highestGross Margin % of Co-Diagnostics was 88.18%. The lowest was 38.56%. And the median was 77.50%.
HAM:C970's Gross Margin % is ranked worse than 61.49% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs HAM:C970: 45.13
Co-Diagnostics had a gross margin of -33.33% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Co-Diagnostics was -6.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Co-Diagnostics had a gross margin of -33.33% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Co-Diagnostics Gross Margin % Related Terms
Co-Diagnostics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs CTSO, NMTC, RDGL: Gross Margin % Comparison
For the Medical Devices subindustry, Co-Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Co-Diagnostics (HAM:C970) has a Gross Margin % of -33.33% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Co-Diagnostics and its competitors. Over the past decade, Co-Diagnostics' Gross Margin % has ranged from 38.56 to 88.18. According to the industry distribution chart, Co-Diagnostics ranks #495 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 61.5%.
Is Co-Diagnostics' Gross Margin % too high?
Co-Diagnostics' current Gross Margin % is -33.33%. Over the past 10 years, this metric has ranged from a low of 38.56 to a high of 88.18. Based on the distribution chart, Co-Diagnostics ranks #495 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Gross Margin % compare to CTSO and NMTC?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #495 out of 805 companies for Gross Margin %. This places Co-Diagnostics in the lower half of its industry. The industry median Gross Margin % is 52.07. Historically, Co-Diagnostics' own Gross Margin % has ranged from 38.56 to 88.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current Gross Margin % is -33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Gross Margin % of -33.33%. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current Gross Margin % is -33.33%. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Gross Margin % is -33.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.
Key valuation signals for HAM:C970:
Gross Margin %: -33.33%
GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score
Get the complete analysis for HAM:C970
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
